449 related articles for article (PubMed ID: 30843184)
1. Bone marrow transplant with post-transplant cyclophosphamide for recessive dystrophic epidermolysis bullosa expands the related donor pool and permits tolerance of nonhaematopoietic cellular grafts.
Ebens CL; McGrath JA; Tamai K; Hovnanian A; Wagner JE; Riddle MJ; Keene DR; DeFor TE; Tryon R; Chen M; Woodley DT; Hook K; Tolar J
Br J Dermatol; 2019 Dec; 181(6):1238-1246. PubMed ID: 30843184
[TBL] [Abstract][Full Text] [Related]
2. Reduced Intensity Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Pediatric Inherited Immune Deficiencies and Bone Marrow Failure Syndromes.
Klein OR; Bapty S; Lederman HM; Younger MEM; Zambidis ET; Jones RJ; Cooke KR; Symons HJ
J Clin Immunol; 2021 Feb; 41(2):414-426. PubMed ID: 33159275
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow transplantation for recessive dystrophic epidermolysis bullosa.
Wagner JE; Ishida-Yamamoto A; McGrath JA; Hordinsky M; Keene DR; Woodley DT; Chen M; Riddle MJ; Osborn MJ; Lund T; Dolan M; Blazar BR; Tolar J
N Engl J Med; 2010 Aug; 363(7):629-39. PubMed ID: 20818854
[TBL] [Abstract][Full Text] [Related]
4. Alternative Donor Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Refractory Severe Aplastic Anemia.
DeZern AE; Zahurak M; Symons H; Cooke K; Jones RJ; Brodsky RA
Biol Blood Marrow Transplant; 2017 Mar; 23(3):498-504. PubMed ID: 28013015
[TBL] [Abstract][Full Text] [Related]
5. Transplanted bone marrow-derived circulating PDGFRα+ cells restore type VII collagen in recessive dystrophic epidermolysis bullosa mouse skin graft.
Iinuma S; Aikawa E; Tamai K; Fujita R; Kikuchi Y; Chino T; Kikuta J; McGrath JA; Uitto J; Ishii M; Iizuka H; Kaneda Y
J Immunol; 2015 Feb; 194(4):1996-2003. PubMed ID: 25601922
[TBL] [Abstract][Full Text] [Related]
6. Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide.
McCurdy SR; Kanakry CG; Tsai HL; Gojo I; Smith BD; Gladstone DE; Bolaños-Meade J; Borrello I; Matsui WH; Swinnen LJ; Huff CA; Brodsky RA; Ambinder RF; Fuchs EJ; Rosner GL; Jones RJ; Luznik L
Biol Blood Marrow Transplant; 2019 Jun; 25(6):1128-1135. PubMed ID: 30599208
[TBL] [Abstract][Full Text] [Related]
7. Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors.
Kanakry JA; Gocke CD; Bolaños-Meade J; Gladstone DE; Swinnen LJ; Blackford AL; Fuchs EJ; Huff CA; Borrello I; Matsui WH; Brodsky RA; Rosner GL; Shanbhag S; Luznik L; Jones RJ; Ambinder RF; Kasamon YL
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2115-2122. PubMed ID: 26183076
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow versus peripheral blood as a graft source for haploidentical donor transplantation in adults using post-transplant cyclophosphamide-A systematic review and meta-analysis.
Yu X; Liu L; Xie Z; Dong C; Zhao L; Zhang J; Gu J; Zhu HH
Crit Rev Oncol Hematol; 2019 Jan; 133():120-128. PubMed ID: 30661648
[TBL] [Abstract][Full Text] [Related]
9. Intravenous allogeneic umbilical cord blood-derived mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa patients.
Lee SE; Lee SJ; Kim SE; Kim K; Cho B; Roh K; Kim SC
JCI Insight; 2021 Jan; 6(2):. PubMed ID: 33491668
[TBL] [Abstract][Full Text] [Related]
10. Immune tolerance of allogeneic haematopoietic cell transplantation supports donor epidermal grafting of recessive dystrophic epidermolysis bullosa chronic wounds.
Ebens CL; McGrath JA; Riedl JA; Keith AR; Lilja G; Rusch S; Keene DR; Tufa SF; Riddle MJ; Shanley R; Van Heest AE; Tolar J
Br J Dermatol; 2021 Jun; 184(6):1161-1169. PubMed ID: 32866988
[TBL] [Abstract][Full Text] [Related]
11. Safety and Wound Outcomes Following Genetically Corrected Autologous Epidermal Grafts in Patients With Recessive Dystrophic Epidermolysis Bullosa.
Siprashvili Z; Nguyen NT; Gorell ES; Loutit K; Khuu P; Furukawa LK; Lorenz HP; Leung TH; Keene DR; Rieger KE; Khavari P; Lane AT; Tang JY; Marinkovich MP
JAMA; 2016 Nov; 316(17):1808-1817. PubMed ID: 27802546
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa.
Rashidghamat E; Kadiyirire T; Ayis S; Petrof G; Liu L; Pullabhatla V; Ainali C; Guy A; Aristodemou S; McMillan JR; Ozoemena L; Mee J; Pramanik R; Saxena A; Nuamah R; de Rinaldis E; Serrano S; Maurin C; Martinez-Queipo M; Lwin SM; Ilic D; Martinez A; Dazzi F; Slaper-Cortenbach I; Westinga K; Zeddies S; van den Broek M; Onoufriadis A; Mellerio JE; McGrath JA
J Am Acad Dermatol; 2020 Aug; 83(2):447-454. PubMed ID: 31786163
[TBL] [Abstract][Full Text] [Related]
13. Interrogation of RDEB Epidermal Allografts after BMT Reveals Coexpression of Collagen VII and Keratin 15 with Proinflammatory Immune Cells and Fibroblasts.
Riedl JA; Riddle M; Xia L; Eide C; Boull C; Ebens CL; Tolar J
J Invest Dermatol; 2022 Sep; 142(9):2424-2434. PubMed ID: 35304249
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow stem cell therapy for recessive dystrophic epidermolysis bullosa.
Kiuru M; Itoh M; Cairo MS; Christiano AM
Dermatol Clin; 2010 Apr; 28(2):371-82, xii-xiii. PubMed ID: 20447506
[TBL] [Abstract][Full Text] [Related]
15. Treatment of dystrophic epidermolysis bullosa with bone marrow non-hematopoeitic stem cells: a randomized controlled trial.
El-Darouti M; Fawzy M; Amin I; Abdel Hay R; Hegazy R; Gabr H; El Maadawi Z
Dermatol Ther; 2016; 29(2):96-100. PubMed ID: 26439431
[TBL] [Abstract][Full Text] [Related]
16. Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigen-Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic Malignancies.
Jacoby E; Chen A; Loeb DM; Gamper CJ; Zambidis E; Llosa NJ; Huo J; Cooke KR; Jones R; Fuchs E; Luznik L; Symons HJ
Biol Blood Marrow Transplant; 2016 Jan; 22(1):112-8. PubMed ID: 26343947
[TBL] [Abstract][Full Text] [Related]
17. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
18. An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease.
Kassim AA; de la Fuente J; Nur E; Wilkerson KL; Alahmari AD; Seber A; Bonfim C; Simões BP; Alzahrani M; Eckrich MJ; Horn B; Hanna R; Dhedin N; Rangarajan HG; Gouveia RV; Almohareb F; Aljurf M; Essa M; Alahmari B; Gatwood K; Connelly JA; Dovern E; Rodeghier M; DeBaun MR
Blood; 2024 Jun; 143(25):2654-2665. PubMed ID: 38493482
[TBL] [Abstract][Full Text] [Related]
19. Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation.
Nagler A; Aker M; Or R; Naparstek E; Varadi G; Brautbar C; Slavin S
Exp Hematol; 2001 Mar; 29(3):362-70. PubMed ID: 11274765
[TBL] [Abstract][Full Text] [Related]
20. A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa.
Venugopal SS; Yan W; Frew JW; Cohn HI; Rhodes LM; Tran K; Melbourne W; Nelson JA; Sturm M; Fogarty J; Marinkovich MP; Igawa S; Ishida-Yamamoto A; Murrell DF
J Am Acad Dermatol; 2013 Dec; 69(6):898-908.e7. PubMed ID: 24075228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
